| Year |
Citation |
Score |
| 2020 |
Kao C, Powers E, Datto MB, Green M, Harrison MR, Armstrong AJ, George DJ, Clarke JM, Strickler JH, Zhang T. Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors. Journal of Clinical Oncology. 38: 80-80. DOI: 10.1200/Jco.2020.38.5_Suppl.80 |
0.352 |
|
| 2020 |
Watson C, Tait S, Soo L, Plichta JK, Zhang T, Castellar E, Armstrong AJ, Previs RA, Strickler JH, Green M, Datto M, Marcom PK, Menendez CS. The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board. Journal of Clinical Oncology. 38: 1516-1516. DOI: 10.1200/Jco.2020.38.15_Suppl.1516 |
0.376 |
|
| 2019 |
Zhu J, Tucker MD, Kao C, Labriola M, Cheris S, Datto MB, Wu Y, Healy P, Gupta S, Kirtane K, Gupta RT, Marin D, Zhang T, McNamara MA, Harrison MR, et al. Immune checkpoint inhibitor response in tumors with LRP1B variants. Journal of Clinical Oncology. 37: e14291-e14291. DOI: 10.1200/Jco.2019.37.15_Suppl.E14291 |
0.347 |
|
| 2018 |
Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, et al. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems. PMID 30268436 DOI: 10.1016/J.Cels.2018.08.010 |
0.365 |
|
| 2018 |
Korkut A, Zaidi S, Kanchi R, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Schultz A, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, et al. Abstract 3413: A pan-cancer atlas of genomic, epigenomic and transcriptomic alterations in the TGF-β pathway Cancer Research. 78: 3413-3413. DOI: 10.1158/1538-7445.Am2018-3413 |
0.386 |
|
| 2017 |
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. The Journal of Molecular Diagnostics : Jmd. 19: 4-23. PMID 27993330 DOI: 10.1016/J.Jmoldx.2016.10.002 |
0.316 |
|
| 2016 |
Jiang XS, Harrison GP, Datto MB. Young investigator challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Cancer. PMID 27893191 DOI: 10.1002/Cncy.21802 |
0.333 |
|
| 2014 |
Stevenson M, Christensen J, Shoemaker D, Foster T, Barry WT, Tong BC, Wahidi M, Shofer S, Datto M, Ginsburg G, Crawford J, D'Amico T, Ready N. Tumor acquisition for biomarker research in lung cancer. Cancer Investigation. 32: 291-8. PMID 24810245 DOI: 10.3109/07357907.2014.911880 |
0.339 |
|
| 2014 |
Zessin AS, Randall A, McCall S, Datto MB, Hsu SD. Identification and validation of actionable mutations in solid tumors. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E22149 |
0.341 |
|
| 2013 |
Uronis JM, VanDeusen JB, Datto MB, Lucas J, Morse M, Mantyh C, Lyerly HK, Clary BM, Hsu SD. A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease. Journal of Clinical Oncology. 31: 339-339. DOI: 10.1200/Jco.2013.31.4_Suppl.339 |
0.364 |
|
| 2012 |
Kernagis D, Datto M, McLendon R, Grant GA. 164 L1CAM as a Marker of an Aggressive Tumor Phenotype in Children with Juvenile Pilocytic Astrocytoma. Neurosurgery. 71: E565. PMID 28175762 DOI: 10.1227/01.Neu.0000417754.93159.A8 |
0.649 |
|
| 2012 |
VanDeusen JB, Uronis J, Morse M, Gatza ML, Datto MB, Mantyh C, Lyerly HK, Nevins JR, Clary BM, Hsu SD. Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 447. PMID 27983186 DOI: 10.1200/Jco.2012.30.4_Suppl.447 |
0.385 |
|
| 2012 |
Kernagis DN, Hall AH, Datto MB. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival. The Journal of Molecular Diagnostics : Jmd. 14: 214-22. PMID 22490445 DOI: 10.1016/J.Jmoldx.2012.01.007 |
0.688 |
|
| 2012 |
Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Molecular Cancer Therapeutics. 11: 1500-9. PMID 22351745 DOI: 10.1158/1535-7163.Mct-11-0937 |
0.376 |
|
| 2012 |
Barry W, Marcom P, Geradts J, Datto M. Abstract P4-09-01: Retrospective evaluation of precision of gene-expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-09-01 |
0.426 |
|
| 2012 |
Kuderer N, Barry W, Geradts J, Ginsburg G, Lyman G, Datto M, Liotcheva V, Isner P, Veldman T, Agarwal P, Hwang S, Ready N, Marcom P. Abstract P2-10-03: A cross-platform comparison of genomic signatures and OncotypeDx score to discover potential prognostic/predictive genes and pathways Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-10-03 |
0.378 |
|
| 2011 |
Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (New York, N.Y.). 13: 758-70. PMID 21847367 DOI: 10.1593/Neo.11528 |
0.366 |
|
| 2011 |
Barry W, Chen W, Sfakianos G, Isner P, Datto M, Kuderer N, Lyman G, Abernethy A, Ginsburg G, Berchuck A. OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts. European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72620-X |
0.338 |
|
| 2010 |
Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2198-206. PMID 20368555 DOI: 10.1200/Jco.2009.26.7245 |
0.675 |
|
| 2010 |
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR. A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 107: 6994-9. PMID 20335537 DOI: 10.1073/Pnas.0912708107 |
0.404 |
|
| 2010 |
Marcom PK, Barry W, Datto MB, Geradts J, Olson JA, Marks J, Lyman GH, Potti A, Ginsburg GS, Nevins JR. A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer. Journal of Clinical Oncology. 28: TPS102-TPS102. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps102 |
0.405 |
|
| 2010 |
Potti A, Vlahovic G, Dunphy F, Barry W, Datto MB, D'Amico TA, Crawford J, Ginsburg GS, Nevins JR, Ready N. Implementing genomically-guided trials in non-small cell lung carcinoma (NSCLC). Journal of Clinical Oncology. 28: e18003-e18003. DOI: 10.1200/Jco.2010.28.15_Suppl.E18003 |
0.308 |
|
| 2010 |
Barry W, Acharya C, Datto MB, Dressman HK, Marcom PK, Ready N, Ginsburg GS, Potti A, Nevins JR. Utilization of genomic signatures for chemotherapy response in prospective clinical studies. Journal of Clinical Oncology. 28: 10513-10513. DOI: 10.1200/Jco.2010.28.15_Suppl.10513 |
0.331 |
|
| 2009 |
Marcom PK, Datto MB, Barry WT, Geradts J, Foster TL, Dressman HK, Olson J, Potti A, Ginsburg G, Nevins JR. Implementation of genomic predictors of chemotherapy response for guiding preoperative therapy in a prospective breast cancer trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11057. PMID 27963164 DOI: 10.1200/Jco.2009.27.15_Suppl.11057 |
0.354 |
|
| 2009 |
Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, Foster EH, Lathia JD, Rich JN, Wang XF, Datto MB. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. The Journal of Biological Chemistry. 284: 25160-9. PMID 19592488 DOI: 10.1074/Jbc.M109.012484 |
0.338 |
|
| 2009 |
Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ, Chu CT. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathology (Zurich, Switzerland). 19: 439-48. PMID 18652591 DOI: 10.1111/J.1750-3639.2008.00196.X |
0.311 |
|
| 2009 |
Lanasa MC, Davis PH, Datto M, Cook H, Rizzieri DA. Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL. Blood. 114: 3430-3430. DOI: 10.1182/Blood.V114.22.3430.3430 |
0.324 |
|
| 2008 |
Barry WT, Datto M, Geradts J, Foster T, Olson J, Marcom PK, Dressman HK, Nevins JR, Ginsburg G, Potti A. Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11068. PMID 27947719 DOI: 10.1200/Jco.2008.26.15_Suppl.11068 |
0.396 |
|
| 2008 |
Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, Wang XF. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes & Development. 22: 308-21. PMID 18245446 DOI: 10.1101/Gad.1632008 |
0.352 |
|
| 2005 |
Robboy SJ, Datto MB. Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries? Human Pathology. 36: 597-9. PMID 16021564 DOI: 10.1016/J.Humpath.2005.05.012 |
0.319 |
|
| 2001 |
Decesse JT, Medjkane S, Datto MB, Crémisi CE. RB regulates transcription of the p21/WAF1/CIP1 gene. Oncogene. 20: 962-971. PMID 11314031 DOI: 10.1038/Sj.Onc.1204169 |
0.31 |
|
| 1999 |
Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. The Journal of Biological Chemistry. 274: 35053-8. PMID 10574984 DOI: 10.1074/Jbc.274.49.35053 |
0.312 |
|
| 1998 |
Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Molecular Biology of the Cell. 9: 3309-19. PMID 9843571 DOI: 10.1091/Mbc.9.12.3309 |
0.303 |
|
| 1997 |
Datto MB, Hu PPC, Kowalik TF, Yingling J, Wang XF. The viral oncoprotein E1A blocks transforming growth factor β-mediated induction of p21/WAF1/Cip1 and p15/INK4B Molecular and Cellular Biology. 17: 2030-2037. PMID 9121451 DOI: 10.1128/Mcb.17.4.2030 |
0.306 |
|
| 1995 |
Datto MB, Yu Y, Wang X. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. Journal of Biological Chemistry. 270: 28623-28628. PMID 7499379 DOI: 10.1074/Jbc.270.48.28623 |
0.305 |
|
| Show low-probability matches. |